Price
$4.63
Decreased by -5.51%
Dollar Volume
3.33 M
ADR%
9.59
Earnings Report Date (estimate)
Nov 8, 22 (-0.49)
Market Cap.
359.50 M
Shares Float
41.66 M
Shares Outstanding
77.65 M
Beta
0.95
Price / Earnings
-1.82
BPR
18.18
20D Range
3.32 5.75
50D Range
2.69 5.75
200D Range
2.69 13.61
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 8, 22 -0.65
Increased by +30.11%
-0.35
Decreased by -85.71%
Aug 9, 22 -0.84
Increased by +12.50%
-0.91
Increased by +7.69%
May 9, 22 -0.22
Increased by +67.16%
-0.70
Increased by +68.57%
Mar 3, 22 -0.45
Increased by +38.36%
-0.86
Increased by +47.67%
Nov 2, 21 -0.93
Decreased by -20.78%
-0.92
Decreased by -1.09%
Aug 3, 21 -0.96
Decreased by -31.51%
-0.86
Decreased by -11.63%
May 6, 21 -0.67
Increased by +79.60%
-0.90
Increased by +25.56%
Mar 18, 21 -0.73
Decreased by -208.15%
-0.38
Decreased by -92.11%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 76.32 M
Increased by +N/A%
-50.61 M
Increased by +60.01%
Decreased by -66.31%
Decreased by N/A%
Sep 30, 21 13.15 M
Increased by +N/A%
-71.55 M
Decreased by -128.29%
Decreased by -544.22%
Decreased by N/A%
Jun 30, 21 3.76 M
Increased by +60.68%
-72.57 M
Decreased by -45.55%
Decreased by -1.93 K%
Increased by +9.42%
Sep 30, 20 0.00 - -20.33 M -
Decreased by N/A%
-
Jun 30, 20 0.00 - -126.56 M -
Decreased by N/A%
-
Sep 30, 19 0.00 - -31.34 M -
Decreased by N/A%
-
Jun 30, 19 2.34 M - -49.86 M -
Decreased by -2.13 K%
-
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.